
Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:


1. (Currently amended) A compound for modulating c-Kit activity according to Formula I,



or a pharmaceutically acceptable salt, thereof, wherein,

ring A is:

	(R ¹) ₀₋₃	
X	$\left\{\begin{array}{c} Z & 1 \\ \hline 1 & 1 \\ N - 1 & N \end{array}\right\}$ $(R^1)_{0-2}$	$(R^1)_{0-1}$
(R ¹) ₀₋₁	Z	N
(R ¹) ₀₋₄	$(R^1)_{0-5}$ Z Z Y Y	(R ¹) ₀₋₅ Y



- wherein each Y is independently either =C(H)- or =N-; and Z is selected from -O-, -S-, and- $N(R^7)$ -, provided that the A ring contains at least one annular N, O, or S;
- each R^1 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- two adjacent of R^1 , together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R^{10} ;

L¹ is a single bond;

ring B is phenyl;

- each R^2 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted heterocyclyl C_{1-6} alkyl;
- two adjacent of R^2 , together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R^{15} ;
- L^2 is selected from -N(H)N(H)C(=O)N(H)-, -CH₂N(H)C(=O)N(H)-, -CH₂OC(=O)N(H)-, and -XCH₂C(=O)N(H)-; wherein X is selected from -O-, -S(O)₀₋₂-, and -N(R⁷)-; and any C-H of L^2 is optionally C-R²⁰;

ring C is phenyl;

- each R^3 is independently selected from halogen, trihalomethyl, $-CN,-NO_2$, $-OR^4$, $-N(R^4)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^4)R^4$, $-C(=O)N(R^4)R^4$, $-C(=NR^5)N(R^4)R^4$, $-C(=NR^5)R^4$, $-N(R^4)SO_2R^4$, $-N(R^4)C(O)R^4$, $-NCO_2R^4$, $-C(=O)R^4$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; provided R^3 is not a cyclic sulfonamide attached to ring C via the nitrogen of said cyclic sulfonamide, wherein there exists at least one of R^3 that is halogen or trihalomethyl;
- R^4 is selected from -H, optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted aryl, optionally substituted aryl $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl;
- two of R⁴, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- R^5 is selected from -H, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -CO₂R⁴, optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted $C_{1\text{-}6}$ alkenyl, and optionally substituted $C_{1\text{-}6}$ alkynyl;
- R^7 is selected from -H, optionally substituted $C_{1\text{-}6}$ alkyl, -SO₂N(R^4) R^4 , -CO₂ R^4 , -C(=O)N(R^4) R^4 , -C(=N R^5)N(R^4) R^4 , -C(=N R^5) R^4 , -C(=O) R^4 , optionally substituted alkoxy, optionally substituted aryl $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl; and
- each of R^{10} , each of R^{15} , each of R^{20} , and each of R^{25} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl

 $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl;

provided:

the compound is not one of:

N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide,

N-(4-chloro-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide,

N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide

N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide

N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide

2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[2-(trifluoromethyl)phenyl]acetamide

2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-[3-(trifluoromethyl)phenyl]acetamide

N-[2-chloro-5-(trifluoromethyl) phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide

N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide or

N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide.

2-12. (Cancelled)

- 13. (Canceled)
- 14. (Original) The compound according to claim 13, wherein ring C is a phenyl comprising a trifluoromethyl radical meta- to L^2 .
- 15. (Previously presented) The compound according to claim 1, wherein each of R^3 is independently selected from halogen, trihalomethyl, $-OR^4$, $-C(=O)R^4$, and optionally substituted C_{1-6} alkyl.
- 16. (Currently amended) A compound for modulating c-Kit activity according to the following Formula:

$$(R^{26})_{0-4}$$
 $(R^{30})_{1-8}$
 $(R^{30})_{1-8}$
 $(R^{30})_{1-8}$

or a pharmaceutically acceptable salt, thereof, wherein,

W is selected from the following:

	(R ²⁷) ₀₋₃	
Z	$Z = \frac{1}{\ \cdot \ } $ $(R^{27})_{0-2}$	$(R^{27})_{0-1}$
N Z N N N (R ²⁷) ₀₋₁	$ \begin{array}{c c} Z & & \\ \hline & & \\ N & N \\ (R^{27})_{0-1} \end{array} $	Z N
(R ²⁷) ₀₋₄ Y—Y—Y—Y—Y—Y—Y—Y—Y——Y—————————————————	(R ²⁷) ₀₋₅ Y Z Z	(R ²⁷) ₀₋₅ Y Y Y Z Z Z
(R ²⁷) ₀₋₆ Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	$(\mathbb{R}^{27})_{0-6} \qquad \qquad$	$(R^{27})_{0-6} \xrightarrow{\overset{\checkmark}{}} \overset{\overset{\checkmark}{}}{\overset{\checkmark}{}} \overset{\overset{\checkmark}{}}{\overset{\checkmark}{}} \overset{\overset{\checkmark}{}}{\overset{\checkmark}{}} \overset{\overset{\checkmark}{}}{}}$

each of R^{27} independently selected from halogen, trihalomethyl, -CN, -NO₂, -OR⁵⁵, -S(O)₀₋₂R⁵⁵, -SO₂N(R⁵⁵)R⁵⁵, -C(=O)N(R⁵⁵)R⁵⁵, -C(=NR⁵⁰)N(R⁵⁵)R⁵⁵, -C(=NR⁵⁰)R⁵⁵, -N(R⁵⁵)SO₂R⁵⁵, -N(R⁵⁵)C(O)R⁵⁵, -NCO₂R⁵⁵, -C(=O)R⁵⁵, optionally substituted alkoxy, optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl;

each Y is independently either =C(H)- or =N-;

Z is selected from -O-, -S(O) $_{0-2}$ -, and -N(R 7)-,

provided that the W ring contains at least one annular annular N, O, or S;

E and G are each independently selected from -O-, -S(O)₀₋₂-, -C(R³¹)R³²-, and -N(R³³)-; J_1 and J_2 are each independently =C(H)- or =N-;

- R^{26} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -CO₂R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)R⁴⁰, -N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- R^{30} is independently selected from halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)R⁴⁰, -N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl C_{1-6} alkyl, wherein there exists at least one of R^{30} that is trihalomethyl;
- R^{31} and R^{32} are each independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -CO₂R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)R⁴⁰, -N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- R^{33} is selected from -H, optionally substituted lower alkyl, $-SO_2N(R^{40})R^{40}$, $-CO_2R^{40}$, $-C(=O)N(R^{40})R^{40}$, $-C(=NR^{50})N(R^{40})R^{40}$, $-C(=NR^{50})R^{40}$, $-C(=O)R^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted heterocyclyl C_{1-6} alkyl;

- R^{40} is selected from -H, optionally substituted alkoxy, optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted aryl $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl;
- two of R⁴⁰, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- R^{50} is selected from -H, -CN, -NO₂, -OR⁴⁰, -S(O)₀₋₂R⁴⁰, -CO₂R⁴⁰, optionally substituted C_{1-6} alkyl, optionally substituted C_{1-6} alkenyl, and optionally substituted C_{1-6} alkynyl;
- R^{55} is selected from -H, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; and
- two of R⁵⁵, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P.
- 17. (Cancelled)
- 18. (Currently amended) The compound according to claim 16, wherein R³⁰ is selected from halogen, trihalomethyl, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted aryl C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl, wherein there exists at least one of R³⁰ that is trifluoromethyl.
- 19. (Cancelled)
- 20. (Cancelled)
- 21. (Cancelled)
- 22. (Cancelled)

- 23. (Withdrawn) The compound according to claim 16, wherein E is selected from -O-, -S(O)₀₋₂-, and -NH-; and G is -CH₂-.
- 24. (Withdrawn) The compound according to claim 16, wherein E is either -CH₂- or -NH-; and G is selected from -O-, -S-, and -NH-.
- 25. (Cancelled)
- 26. (Cancelled)
- 27. (Previously presented) A compound selected from the following Table:

Entry	Name	Structure
1	N-[5-chloro-2-(methyloxy)phenyl]-2-{[3- (1H-tetrazol-1-yl)phenyl]oxy}acetamide	CH ₃ O NH N N N N N N N N N N N N N N N N N
4	N-(2-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N = N CI
5	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N
7	N-(3-chloro-2-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N = N CH ₃ CI

Entry	Name	Structure
8	N-(3-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N=N ON NH
9	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2H-tetrazol-5- yl)phenyl]oxy}acetamide	N H CI
10	N-(4-chloro-2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N, N, N CI
11	N-(4-bromo-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N. N. N. CH ₃
13	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N. N

Entry	Name	Structure
14	N-[4-bromo-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N. N. N. P. F.
15	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N CI F F N=N
16	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	CH ₃ H F F CI
17	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(5-methyl-1H-tetrazol-1- yl)phenyl]oxy}acetamide	N CH ₃ O N F F F
18	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-methyl-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CH ₃ H F F CI

Entry	Name	Structure
19	N-(4-chlorophenyl)-N-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N. N. CH ³
20	N-[4-chloro-2-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N.N.N.
23	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N, N N, N O H N F F
24	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2-methyl-2H-tetrazol-5- yl)phenyl]oxy}acetamide	H ₃ C H CI
25	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,4-dichloro-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	

Entry	Name	Structure
26	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]thio}acetamide	LAZ - Z - Z - Z - Z - Z - Z - Z - Z - Z -
27	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	N.N.N. H. N. P. F.
28	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	
37	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-4-ylphenyl)oxy]acetamide	N CI F F
38	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-methyl-N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	CH ₃ O CH ₅ F F

Entry	Name	Structure
49	N-[5-chloro-2,4-bis(methyloxy)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N.N. N CI
52	N-[2-(methyloxy)-5- (trifluoromethyl)phenyl]-2-{[3-(1H- tetrazol-1-yl)phenyl]oxy}acetamide	N.N. N. H. F.
57	1,1-dimethylethyl 2-{3-[(2-{[4-chloro-3- (trifluoromethyl)phenyl]amino}-2- oxoethyl)oxy]phenyl}-1H-pyrrole-1- carboxylate	LON ON FFFF
58	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-pyrrol-2-yl)phenyl]oxy}acetamide	ON H F F
59	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyrimidin-5-ylphenyl)oxy]acetamide	N O N F F F

Entry	Name	Structure
60	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	N.N.N.
63	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-3-ylphenyl)oxy]acetamide	O N F F F
68	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(3,5-dimethylisoxazol-4- yl)phenyl]oxy}acetamide	$\begin{array}{c} & & \\ & \\ & \\ \\ & \\ \\ & \\ \\ & \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$
69	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-quinolin-7-ylphenyl)oxy]acetamide	ON PER F
71	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	N. N. H. H. F.

Entry	Name	Structure
73	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	N F F F CI
75	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-tetrazol-1-yl)phenyl]methyl}urea	N CI F F
77	N-[4-fluoro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	NN NN FFFF
79	N-[2-fluoro-5-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	F F F N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.
80	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	O N F F F
81	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyrimidin-5-ylphenyl)methyl]urea	N N N N F F

Entry	Name	Structure
82	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyrimidin-5-ylphenyl)methyl]urea	CI FFFF
83	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	NH NH FFFF
84	[3-(1H-tetrazol-1-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	N. N. H. F.
85	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	N F F F
86	N~2~-[4-chloro-3- (trifluoromethyl)phenyl]-N-[3-(1H- tetrazol-1-yl)phenyl]glycinamide	N. N. N. H. N. F.

Entry	Name	Structure
87	2-{[4-chloro-3- (trifluoromethyl)phenyl]oxy}-N-[3-(1H- tetrazol-1-yl)phenyl]acetamide	N. N. N. P.
88	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-methyl-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	H ₃ C CI F F F F
89	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	ON PEN CI
90	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F CI F F F F
91	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F O NH F F

Entry	Name	Structure
94	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	ON H F F F
95	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide	H ₃ C ₂ O ₁ O ₁ O ₁ O ₂ O ₁ O ₂ O ₂ O ₃ O ₄ O ₄ O ₅ O ₅ O ₆ O ₆ O ₇
96	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-chloro-3-(trifluoromethyl)phenyl]acetamide	H ₃ C ₂ O N F F F
97	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-4-ylphenyl)oxy]acetamide	O N F F
98	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(methyloxy)-4-(1H-tetrazol-1- yl)phenyl]glycinamide	H ₃ C ² O H O H F F F F

Entry	Name	Structure
99	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(methyloxy)-3-(1H-tetrazol-1- yl)phenyl]glycinamide	N. N. N. H. N. F. F. F. CI
100	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(1H-tetrazol-1- yl)phenyl]glycinamide	N N N N N N N N N N N N N N N N N N N
101	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (2,3,5,6-tetrafluoro-4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	F IN NH F F
102	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-tetrazol-1-yl)phenyl]methyl}urea	ON H F F F
103	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
104	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-3-ylphenyl)methyl]urea	N N N F F
105	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- methyl-2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	N. N. N. P. F.
106	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	CI FF CH ₃
107	N-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₃ C ₁ C ₁ H ₃ C ₁ C ₁ C ₁ F ₁ F ₁ F ₁ C ₁ C ₁ C ₁ F ₁ C
108	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H ₃ C' ^O N F _F

Entry	Name	Structure
109	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C ^{-O} N O CI F F F F
110	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H ₃ C ₂ O N N N N N N N N N N N N N N N N N N N
111	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C ₂ O _N H H F F
114	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(2H-tetrazol-5- yl)phenyl]glycinamide	N=N HN.N
115	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,6-difluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F O N F F F

Entry	Name	Structure
116	(3-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI F F F
117	(3-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	N CI F F F
118	(3-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI F F F
119	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [4-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	H, N H F F F
120	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-3- ylphenyl)hydrazinecarboxamide	N. N. N. N. F. F. F.

Entry	Name	Structure
121	(4-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	ON FFFF
122	(4-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI F F F
123	(4-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	ON H F F
124	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-4-ylphenyl)methyl]urea	N N N F F
125	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-3- ylphenyl)hydrazinecarboxamide	H. N. H. F. F. F.

Entry	Name	Structure
126	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyrimidin-5- ylphenyl)hydrazinecarboxamide	N N N N N N N N N N N N N N N N N N N
127	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(4-pyrimidin-5-ylphenyl)methyl]urea	N CI O'CH ₃
128	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(4-pyridin-3-ylphenyl)methyl]urea	N N CH ₃
129	(4-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate	N CI O CH ₃
130	(4-pyridin-3-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate	N CI O'CH3

Entry	Name	Structure
131	1-(4-pyridin-3-ylphenyl)ethyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	CH ₃ O N F F F
132	1-(4-pyrimidin-5-ylphenyl)ethyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CH ₃ O CI FFFF
133	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(3-pyridin-3-ylphenyl)methyl]urea	N O CH ₃
134	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(3-pyrimidin-5-ylphenyl)methyl]urea	N CH ₃
135	(3-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	CI CH ₃

Entry	Name	Structure
136	(3-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate	N CH ₃
138	N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	N N N F F F
143	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyridin-3-ylphenyl)ethyl]urea	CH ₃ O CI N N F F
144	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyrimidin-5-ylphenyl)ethyl]urea	CH ₃ O CI F F F
145	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-indol-2-yl)phenyl]oxy}acetamide	O P F F F F

Entry	Name	Structure
147	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-4- ylphenyl)hydrazinecarboxamide	THE PROPERTY OF THE PROPERTY O
148	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-4- ylphenyl)hydrazinecarboxamide	N N N N F F
149	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-4-ylphenyl)methyl]urea	N N N F F
150	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-quinoxalin-6-ylphenyl)methyl]urea	N CI FFF
152	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-quinoxalin-6-ylphenyl)methyl]urea	N N N F F F

Entry	Name	Structure
155	[3-(1H-tetrazol-1-yl)phenyl]methyl [3-chloro-4-(methyloxy)phenyl]carbamate	N=N O H CI
156	N-[3-chloro-4-(methyloxy)phenyl]-N'-{[3-(1H-tetrazol-1-yl)phenyl]methyl}urea	N=N O CH ₃
157	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(5-hydroxy-1H-tetrazol-1- yl)phenyl]oxy}acetamide	HO N F F
160	N-{[3-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N N N F F
161	N-{[4-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N H H F F

Entry	Name	Structure
165	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-fluoropyridin-3- yl)phenyl]methyl}urea	F N N F F F
166	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C.O
167	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-fluoropyridin-3- yl)phenyl]methyl}urea	F N H H F F
168	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	N H H F F F F F
169	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-methylpyridin-3- yl)phenyl]methyl}urea	H ₃ C N

Entry	Name	Structure
171	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-methylpyridin-3- yl)phenyl]methyl}urea	H ₃ C CI F F F
174	[3-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	H ₃ C CI
177	(3-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N O N F F F F
179	N-{[3-(6-acetylpyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₃ C CF ₃
180	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-cyanopyridin-3- yl)phenyl]methyl}urea	NC N O CI CF ₃
185	[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN N CI FF FF

Entry	Name	Structure
188	[3-(1H-benzimidazol-2-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N N N N F F F
190	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-3- yl]phenyl}methyl)urea	S CH ₃ CF ₃
191	[4-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	H ₃ C N
194	(4-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	CI PFF F
195	[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN F F F

Entry	Name	Structure
200	(3-pyridin-3-ylphenyl)methyl [5-chloro-2- (methyloxy)phenyl]carbamate	CH ₃ ON N CI
201	[4-(1H-tetrazol-1-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	ON F F F
202	(3-pyrimidin-5-ylphenyl)methyl [5-chloro-2-(methyloxy)phenyl]carbamate	CH ₃ ON N CI
213	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-pyrazol-4-yl)phenyl]methyl}urea	N N CF ₃
214	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-pyrazol-4-yl)phenyl]methyl}urea	HN CF ₃

Entry	Name	Structure
215	[3-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN CF ₃
216	[4-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CF ₃ CI
217	N-{[3-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	N CI O CF ₃
218	N-{[4-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N CF3
219	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(2-fluoropyridin-3- yl)phenyl]methyl}urea	N F CF ₃

Entry	Name	Structure
220	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(2-fluoropyridin-3- yl)phenyl]methyl}urea	N CF ₃
221	[3-(1H-tetrazol-1-yl)phenyl]methyl [3- (trifluoromethyl)phenyl]carbamate	N.N. N. H. F. F. F.
224	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-2- yl]phenyl}methyl)urea	H ₃ C ^{-S} N O CF ₃
225	[3-(2,6-dimethylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₃ C CF ₃
226	{3-[5-(methyloxy)pyridin-3-yl]phenyl}methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O CH ₃ O N CI CF ₃

Entry	Name	Structure
229	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-isoquinolin-4-ylphenyl)methyl]urea	ST CF ³
230	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-isoquinolin-4-ylphenyl)methyl]urea	NH NH CF3
232	[3-(1H-pyrazol-4-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	N N P F F F
233	[4-(1H-pyrazol-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HNN FF

- 28. (Previously presented) A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
- 29. (Cancelled)
- 30. (Withdrawn) A method for modulating the *in-vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound according to claim 1.
- 31. (Withdrawn) The method according to claim 30, wherein the kinase is c-Kit.

- 32. (Withdrawn) The method according to claim 31, wherein modulating the *in vivo* activity of c-Kit comprises inhibition of c-Kit.
- 33. (Withdrawn) A method of treating rheumatoid arthritis, graft-host diseases, multiple sclerosis, psoriasis; artheroscrosis, myocardioinfarction, ischemia, stroke, restenosis; interbowel diseases, osteoarthritus, macular degeneration, or diabetic retinopathy, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in claim 1.
- 34. (Withdrawn) A method of screening for modulators of c-Kit, the method comprising combining the compound according to claim 1 and at least one candidate agent and determining the effect of the candidate agent on c-Kit activity.
- 35. (Withdrawn) A method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of a composition comprising the compound according to claim 1 to a cell or a plurality of cells.